Drug Profile
VX 150
Alternative Names: VX-150Latest Information Update: 26 Oct 2022
Price :
$50
*
At a glance
- Originator Vertex Pharmaceuticals
- Class Analgesics; Small molecules
- Mechanism of Action Nav1.8 voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Pain
Most Recent Events
- 23 Sep 2022 Vertex Pharmaceuticals completes a phase-I trial in Pain in United Kingdom (PO) (NCT05418712)
- 16 Jun 2022 Phase-I clinical trials in Pain (In volunteers) in United Kingdom (PO) (NCT05418712)
- 14 Jun 2022 Vertex Pharmaceuticals plans a phase I trial for Pain (PO) in June 2022 (NCT05418712)